Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3559161rdf:typepubmed:Citationlld:pubmed
pubmed-article:3559161lifeskim:mentionsumls-concept:C0005586lld:lifeskim
pubmed-article:3559161lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:3559161pubmed:dateCreated1987-5-8lld:pubmed
pubmed-article:3559161pubmed:abstractTextTwelve patients (eight men and four women) suffering from manic depressive disorder who were receiving both lithium and antipsychotic medication had their antipsychotic changed to depot haloperidol decanoate, with their lithium medication remaining unchanged. Successful transfer to haloperidol decanoate was achieved with a reduced incidence of extrapyramidal side effects, and 100% compliance in eight patients who all remained free of hypomanic relapse, including four patients with rapid-cycling disorder. By comparison, in the three years before switching to haloperidol decanoate these four patients had required sixteen admissions for hypomanic relapses resulting in thirty-four months in-patient treatment.lld:pubmed
pubmed-article:3559161pubmed:languageenglld:pubmed
pubmed-article:3559161pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3559161pubmed:citationSubsetIMlld:pubmed
pubmed-article:3559161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3559161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3559161pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3559161pubmed:statusMEDLINElld:pubmed
pubmed-article:3559161pubmed:monthJullld:pubmed
pubmed-article:3559161pubmed:issn0268-1315lld:pubmed
pubmed-article:3559161pubmed:authorpubmed-author:BatchelorD...lld:pubmed
pubmed-article:3559161pubmed:authorpubmed-author:LoweM RMRlld:pubmed
pubmed-article:3559161pubmed:issnTypePrintlld:pubmed
pubmed-article:3559161pubmed:volume1 Suppl 1lld:pubmed
pubmed-article:3559161pubmed:ownerNLMlld:pubmed
pubmed-article:3559161pubmed:authorsCompleteYlld:pubmed
pubmed-article:3559161pubmed:pagination53-62lld:pubmed
pubmed-article:3559161pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:meshHeadingpubmed-meshheading:3559161-...lld:pubmed
pubmed-article:3559161pubmed:year1986lld:pubmed
pubmed-article:3559161pubmed:articleTitleDepot neuroleptics and manic depressive psychosis.lld:pubmed
pubmed-article:3559161pubmed:publicationTypeJournal Articlelld:pubmed